Ageing Research Reviews, volume 98, pages 102327

ncRNAs and their impact on dopaminergic neurons: Autophagy pathways in Parkinson's disease

Riya Thapa 1
Ehssan Moglad 2
Muhammad Afzal 3
Gaurav Gupta 4
Asif Ahmad Bhat 1
Waleed Hassan Almalki 5
Imran Kazmi 6
Sami I Alzarea 7
Kumud Pant 8, 9
Haider Ali 10, 11
Keshav Raj Paudel 12
Harish Dureja 13
Thakur Gurjeet Singh 14
Sachin Kumar Singh 15, 16
Kamal Dua 15, 17
Show full list: 15 authors
1
 
School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, India
13
 
Department of Pharmaceutical Sciences, Maharishi Dayanand University, Rohtak, 124001, India
Publication typeJournal Article
Publication date2024-07-01
scimago Q1
wos Q1
SJR3.376
CiteScore19.8
Impact factor12.5
ISSN15681637, 18729649
Abstract
Parkinson's Disease (PD) is a complex neurological illness that causes severe motor and non-motor symptoms due to a gradual loss of dopaminergic neurons in the substantia nigra. The aetiology of PD is influenced by a variety of genetic, environmental, and cellular variables. One important aspect of this pathophysiology is autophagy, a crucial cellular homeostasis process that breaks down and recycles cytoplasmic components. Recent advances in genomic technologies have unravelled a significant impact of ncRNAs on the regulation of autophagy pathways, thereby implicating their roles in PD onset and progression. They are members of a family of RNAs that include miRNAs, circRNA and lncRNAs that have been shown to play novel pleiotropic functions in the pathogenesis of PD by modulating the expression of genes linked to autophagic activities and dopaminergic neuron survival. This review aims to integrate the current genetic paradigms with the therapeutic prospect of autophagy-associated ncRNAs in PD. By synthesizing the findings of recent genetic studies, we underscore the importance of ncRNAs in the regulation of autophagy, how they are dysregulated in PD, and how they represent novel dimensions for therapeutic intervention. The therapeutic promise of targeting ncRNAs in PD is discussed, including the barriers that need to be overcome and future directions that must be embraced to funnel these ncRNA molecules for the treatment and management of PD.
Found 

Top-30

Journals

1
2
3
1
2
3

Publishers

1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST | RIS | BibTex
Found error?